{"url_path":"/sec/tern/8-k/2026-04-27/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1831363/0001193125-26-179062-index.html","accession_number":"0001193125-26-179062","cik":"0001831363","ticker":"TERN","issuer_name":"Terns Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1831363/0001193125-26-179062-index.html","primary_entity_key":"0001831363","primary_entity_name":"Terns Pharmaceuticals, Inc."},"word_count":87,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\nNo.\n  \n\nDescription\n\n99.1\n  \n[Press Release issued by Terns Pharmaceuticals, Inc. on April 27, 2026.](d122087dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nTERNS PHARMACEUTICALS, INC.\n\nDate: April 27, 2026\n \n\n \nBy:\n \n\n/s/ Caryn McDowell\n\n \n\n \n\n \nCaryn McDowell\n\n \n\n \n\n \nChief Legal Officer and Corporate Secretary"}